Exercise or Fasting in Individuals With Type 2 Diabetes Receiving Once-Weekly Basal Insulin Icodec.
Diabetes Obes MetabJul 1, 2026 (epub)
Thomas R Pieber, Harpreet S Bajaj, Gabriele Fluhr et al.
✦ AI-curated · Sources linked
In 30 seconds
This Phase I clinical trial evaluated glucose levels and hypoglycaemia risk in 30 adults with type 2 diabetes receiving once-weekly basal insulin icodec during exercise and fasting. The study found that mean CGM-based time below range < 3.0 mmol/L was 0.3% during exercise and 0.2% during fasting, indicating a low risk of hypoglycaemia.
Key findings
- Mean CGM-based time below range < 3.0 mmol/L was 0.3% during exercise.
- Mean CGM-based time below range < 3.0 mmol/L was 0.2% during fasting.
- No clinically significant or severe hypoglycaemia was reported.
- Intravenous glucose was administered to 15 participants (50%) during fasting.
Why it matters
Understanding the safety profile of insulin icodec during physical activity and fasting is crucial for managing glycaemic control in patients with type 2 diabetes, potentially guiding clinical decisions in similar patient populations.